Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2018

Segment Reporting [Abstract]

Schedule of Segment Information

Selected financial information for the Company’s operating segments is as follows:

		Year Ended December 31,
		2018			2017
Net revenues - External
Clinical Laboratory Operations	$	131,014		$	2,210,318
Hospital Operations		14,417,676			877,898
	$	14,548,690		$	3,088,216
Loss from operations
Clinical Laboratory Operations	$	(2,247,499	)	$	(4,672,768	)
Hospital Operations		(6,434,538	)		(4,800,539	)
Corporate		(4,542,583	)		(6,602,800	)
	$	(13,224,620	)	$	(16,076,107	)
Depreciation and amortization
Clinical Laboratory Operations	$	764,445		$	1,639,954
Hospital Operations		498,352			73,985
Corporate		1,047			1,382
	$	1,263,844		$	1,715,321
Capital expenditures
Clinical Laboratory Operations	$	-		$	-
Hospital Operations		213,105			1,422,002
	$	213,105		$	1,422,002

	Year Ended December 31,
	2018			2017
Total assets
Clinical Laboratory Operations	$	271,426		$	1,503,520
Hospital Operations		13,568,933			2,549,504
Corporate		2,707,416			3,436,773
Assets of AMSG and HTS classified as held for sale		152,171			255,566
Eliminations		(2,500,646	)		(1,454,570	)
	$	14,199,300		$	6,290,794